| Name | Cevipabulin |
| Description | Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line). |
| In vitro | Cevipabulin (0-50 nM, 72 hours) exhibits significant activity (IC50s: 18-40 nM) against ovarian, breast, prostate, and cervical tumor cell lines. At low concentrations (20-40 nM), it induces sub-G1 nuclei, while concentrations above 50 nM result in a pronounced G2-M block [1]. |
| In vivo | In mice, Cevipabulin ( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles; i.v. and p.o.) is active against human tumor xenografts and showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 9 mg/mL (19.36 mM), Sonication is recommended.
|
| Keywords | Cevipabulin | TTI 237 | TTI237 |
| Inhibitors Related | Flubendazole | Mebendazole | N-Phenylbenzylamine | 4-Isopropoxybenzoic acid | Oxfendazole | Thiabendazole | Methylene Blue | Methylene Blue trihydrate | Paclitaxel | 4'-Demethylepipodophyllotoxin |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
